Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Activating mutations in anaplastic lymphoma kinase (ALK) occur in about 10% of neuroblastoma (NB) tumors.
• The function of wild-type (WT) ALK, expressed in most non-mutated NB cases, remains largely unknown.
• Both WT and mutant ALK proteins undergo extracellular domain (ECD) cleavage.

Purpose of the Study:

• To investigate the role of WT ALK ECD cleavage in neuroblastoma pathogenesis.
• To identify the mechanism and functional consequences of WT ALK ECD cleavage.
• To explore therapeutic strategies targeting WT ALK ECD cleavage.

Main Methods:

• Mapping the precise cleavage site of WT ALK ECD.
• Inhibiting WT ALK ECD cleavage using genetic and pharmacologic approaches.
• Assessing the impact of cleavage inhibition on NB cell migration, epithelial-to-mesenchymal transition (EMT) gene expression, and β-catenin activity.
• Investigating the role of matrix metalloproteinase 9 (MMP-9) in ALK ECD cleavage.
• Evaluating the therapeutic efficacy of cleavage inhibition in NB mouse models.

Main Results:

• The cleavage site for WT ALK ECD was mapped to Asn654-Leu655.
• Inhibition of WT ALK ECD cleavage significantly reduced NB cell migration.
• Cleavage inhibition led to the downregulation of an EMT gene signature and decreased nuclear β-catenin.
• Matrix metalloproteinase 9 (MMP-9) was identified as the enzyme mediating WT ALK ECD cleavage.
• Inactivating MMP-9 reduced NB cell migration.
• Inhibition of WT ALK ECD cleavage prolonged survival in NB mouse models.

Conclusions:

• WT ALK ECD cleavage plays a critical role in neuroblastoma progression by promoting cell migration via EMT.
• MMP-9 is a key mediator of this process.
• Targeting WT ALK ECD cleavage presents a potential therapeutic strategy for neuroblastoma.